A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs MP 0250 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Molecular Partners AG
- 05 Jun 2018 Results (n=45) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to a Molecular Partners media release, results will be presented at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO).
- 25 Apr 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History